# PRALUENT

Product · id `cardio:fdaprod-bla125559` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [openFDA record BLA125559](<https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>), retrieved 8 November 2026. No person wrote or checked this page.

Browse, condition area: Coronary and vascular disease  

## In plain language

A biologics license application (BLA) that FDA lists in Drugs@FDA, with an original approval and 8 efficacy supplement approvals on record.

## Technical summary

Drugs@FDA application BLA125559. Original approval 2015-07-24. Efficacy supplement approvals 2017-04-24, 2017-09-20, 2018-08-22, 2019-04-26, 2019-04-26, 2021-04-01, 2024-03-08, 2025-10-09. 2 products listed.

## The registry's words

- Application: BLA125559
- Brand name: PRALUENT
- Applicant: REGENERON PHARMACEUTICALS
- Active ingredient: ALIROCUMAB
- Dosage form: INJECTABLE
- Route: INJECTION

## Claims, with the population each applies to

## Context: FDA record read by the openFDA feed

Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)

### FDA records an approval of BLA125559 on 2015-07-24.

- Category: Regulatory
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Limitations: Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
- Last checked: Not recorded
- Sources:
  1. Supports: Drugs@FDA application BLA125559 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>
     Locator: submissions\[1\].submission\_status\_date. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b.
     How it applies: The decision date as the record writes it.
  2. Supports: Drugs@FDA application BLA125559 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>
     Locator: application\_number. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b.
     How it applies: The registry number of the record.
  3. Supports: Drugs@FDA application BLA125559 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>
     Locator: submissions\[1\].submission\_status. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b.
     How it applies: The decision status as the record writes it.

### FDA records an approval of efficacy supplement 1 to BLA125559 on 2017-04-24.

- Category: Regulatory
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Limitations: Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
- Last checked: Not recorded
- Sources:
  1. Supports: Drugs@FDA application BLA125559 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>
     Locator: submissions\[2\].submission\_status\_date. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b.
     How it applies: The decision date as the record writes it.
  2. Supports: Drugs@FDA application BLA125559 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>
     Locator: application\_number. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b.
     How it applies: The registry number of the record.
  3. Supports: Drugs@FDA application BLA125559 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>
     Locator: submissions\[2\].submission\_status. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b.
     How it applies: The decision status as the record writes it.

### FDA records an approval of efficacy supplement 6 to BLA125559 on 2017-09-20.

- Category: Regulatory
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Limitations: Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
- Last checked: Not recorded
- Sources:
  1. Supports: Drugs@FDA application BLA125559 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>
     Locator: submissions\[8\].submission\_status\_date. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b.
     How it applies: The decision date as the record writes it.
  2. Supports: Drugs@FDA application BLA125559 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>
     Locator: application\_number. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b.
     How it applies: The registry number of the record.
  3. Supports: Drugs@FDA application BLA125559 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>
     Locator: submissions\[8\].submission\_status. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b.
     How it applies: The decision status as the record writes it.

### FDA records an approval of efficacy supplement 14 to BLA125559 on 2018-08-22.

- Category: Regulatory
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Limitations: Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
- Last checked: Not recorded
- Sources:
  1. Supports: Drugs@FDA application BLA125559 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>
     Locator: submissions\[6\].submission\_status\_date. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b.
     How it applies: The decision date as the record writes it.
  2. Supports: Drugs@FDA application BLA125559 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>
     Locator: application\_number. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b.
     How it applies: The registry number of the record.
  3. Supports: Drugs@FDA application BLA125559 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>
     Locator: submissions\[6\].submission\_status. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b.
     How it applies: The decision status as the record writes it.

### FDA records an approval of efficacy supplement 19 to BLA125559 on 2019-04-26.

- Category: Regulatory
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Limitations: Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
- Last checked: Not recorded
- Sources:
  1. Supports: Drugs@FDA application BLA125559 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>
     Locator: submissions\[13\].submission\_status\_date. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b.
     How it applies: The decision date as the record writes it.
  2. Supports: Drugs@FDA application BLA125559 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>
     Locator: application\_number. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b.
     How it applies: The registry number of the record.
  3. Supports: Drugs@FDA application BLA125559 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>
     Locator: submissions\[13\].submission\_status. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b.
     How it applies: The decision status as the record writes it.

### FDA records an approval of efficacy supplement 20 to BLA125559 on 2019-04-26.

- Category: Regulatory
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Limitations: Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
- Last checked: Not recorded
- Sources:
  1. Supports: Drugs@FDA application BLA125559 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>
     Locator: submissions\[7\].submission\_status\_date. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b.
     How it applies: The decision date as the record writes it.
  2. Supports: Drugs@FDA application BLA125559 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>
     Locator: application\_number. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b.
     How it applies: The registry number of the record.
  3. Supports: Drugs@FDA application BLA125559 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>
     Locator: submissions\[7\].submission\_status. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b.
     How it applies: The decision status as the record writes it.

### FDA records an approval of efficacy supplement 29 to BLA125559 on 2021-04-01.

- Category: Regulatory
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Limitations: Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
- Last checked: Not recorded
- Sources:
  1. Supports: Drugs@FDA application BLA125559 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>
     Locator: submissions\[12\].submission\_status\_date. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b.
     How it applies: The decision date as the record writes it.
  2. Supports: Drugs@FDA application BLA125559 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>
     Locator: application\_number. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b.
     How it applies: The registry number of the record.
  3. Supports: Drugs@FDA application BLA125559 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>
     Locator: submissions\[12\].submission\_status. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b.
     How it applies: The decision status as the record writes it.

### FDA records an approval of efficacy supplement 39 to BLA125559 on 2024-03-08.

- Category: Regulatory
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Limitations: Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
- Last checked: Not recorded
- Sources:
  1. Supports: Drugs@FDA application BLA125559 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>
     Locator: submissions\[11\].submission\_status\_date. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b.
     How it applies: The decision date as the record writes it.
  2. Supports: Drugs@FDA application BLA125559 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>
     Locator: application\_number. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b.
     How it applies: The registry number of the record.
  3. Supports: Drugs@FDA application BLA125559 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>
     Locator: submissions\[11\].submission\_status. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b.
     How it applies: The decision status as the record writes it.

### FDA records an approval of efficacy supplement 47 to BLA125559 on 2025-10-09.

- Category: Regulatory
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Limitations: Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
- Last checked: Not recorded
- Sources:
  1. Supports: Drugs@FDA application BLA125559 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>
     Locator: submissions\[10\].submission\_status\_date. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b.
     How it applies: The decision date as the record writes it.
  2. Supports: Drugs@FDA application BLA125559 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>
     Locator: application\_number. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b.
     How it applies: The registry number of the record.
  3. Supports: Drugs@FDA application BLA125559 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125559>
     Locator: submissions\[10\].submission\_status. Retrieved 2026-11-08T02:46:28Z. Source state: Current. Version fingerprint: ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b.
     How it applies: The decision status as the record writes it.

## Guidance, authorization and access

### Regulatory decision `cardio:fdadec-bla125559-approval`

- Product: PRALUENT (`cardio:fdaprod-bla125559`)
- Authority: U.S. Food and Drug Administration (`core:fda`)
- Decision: Approval, 2015-07-24
- Product version: Original application
- Pathway: BLA
- Submission: BLA125559
- Indication: Not stated in the openFDA record
- Jurisdictions: United States
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Basis: claim `cardio:fdaclaim-bla125559-approval`

### Regulatory decision `cardio:fdadec-bla125559-s001`

- Product: PRALUENT (`cardio:fdaprod-bla125559`)
- Authority: U.S. Food and Drug Administration (`core:fda`)
- Decision: Supplemental approval, 2017-04-24
- Product version: Efficacy supplement 1
- Pathway: BLA
- Submission: BLA125559
- Indication: Not stated in the openFDA record
- Jurisdictions: United States
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Basis: claim `cardio:fdaclaim-bla125559-s001`

### Regulatory decision `cardio:fdadec-bla125559-s006`

- Product: PRALUENT (`cardio:fdaprod-bla125559`)
- Authority: U.S. Food and Drug Administration (`core:fda`)
- Decision: Supplemental approval, 2017-09-20
- Product version: Efficacy supplement 6
- Pathway: BLA
- Submission: BLA125559
- Indication: Not stated in the openFDA record
- Jurisdictions: United States
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Basis: claim `cardio:fdaclaim-bla125559-s006`

### Regulatory decision `cardio:fdadec-bla125559-s014`

- Product: PRALUENT (`cardio:fdaprod-bla125559`)
- Authority: U.S. Food and Drug Administration (`core:fda`)
- Decision: Supplemental approval, 2018-08-22
- Product version: Efficacy supplement 14
- Pathway: BLA
- Submission: BLA125559
- Indication: Not stated in the openFDA record
- Jurisdictions: United States
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Basis: claim `cardio:fdaclaim-bla125559-s014`

### Regulatory decision `cardio:fdadec-bla125559-s019`

- Product: PRALUENT (`cardio:fdaprod-bla125559`)
- Authority: U.S. Food and Drug Administration (`core:fda`)
- Decision: Supplemental approval, 2019-04-26
- Product version: Efficacy supplement 19
- Pathway: BLA
- Submission: BLA125559
- Indication: Not stated in the openFDA record
- Jurisdictions: United States
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Basis: claim `cardio:fdaclaim-bla125559-s019`

### Regulatory decision `cardio:fdadec-bla125559-s020`

- Product: PRALUENT (`cardio:fdaprod-bla125559`)
- Authority: U.S. Food and Drug Administration (`core:fda`)
- Decision: Supplemental approval, 2019-04-26
- Product version: Efficacy supplement 20
- Pathway: BLA
- Submission: BLA125559
- Indication: Not stated in the openFDA record
- Jurisdictions: United States
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Basis: claim `cardio:fdaclaim-bla125559-s020`

### Regulatory decision `cardio:fdadec-bla125559-s029`

- Product: PRALUENT (`cardio:fdaprod-bla125559`)
- Authority: U.S. Food and Drug Administration (`core:fda`)
- Decision: Supplemental approval, 2021-04-01
- Product version: Efficacy supplement 29
- Pathway: BLA
- Submission: BLA125559
- Indication: Not stated in the openFDA record
- Jurisdictions: United States
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Basis: claim `cardio:fdaclaim-bla125559-s029`

### Regulatory decision `cardio:fdadec-bla125559-s039`

- Product: PRALUENT (`cardio:fdaprod-bla125559`)
- Authority: U.S. Food and Drug Administration (`core:fda`)
- Decision: Supplemental approval, 2024-03-08
- Product version: Efficacy supplement 39
- Pathway: BLA
- Submission: BLA125559
- Indication: Not stated in the openFDA record
- Jurisdictions: United States
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Basis: claim `cardio:fdaclaim-bla125559-s039`

### Regulatory decision `cardio:fdadec-bla125559-s047`

- Product: PRALUENT (`cardio:fdaprod-bla125559`)
- Authority: U.S. Food and Drug Administration (`core:fda`)
- Decision: Supplemental approval, 2025-10-09
- Product version: Efficacy supplement 47
- Pathway: BLA
- Submission: BLA125559
- Indication: Not stated in the openFDA record
- Jurisdictions: United States
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Basis: claim `cardio:fdaclaim-bla125559-s047`

## Connected pages

- Registry active ingredient is this drug: Alirocumab (`cardio:alirocumab`)

## Provenance

Content hash: be12e7c52f92fca86bc75219f71e6f55c2fc41c50ecae6783d19a518de29ffaa
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
